Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy.

Literature DB >> 26137417

Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy.

Takayuki Ohkuri¹, Arundhati Ghosh², Akemi Kosaka¹, Saumendra N Sarkar³, Hideho Okada⁴.

Abstract

We recently reported that STING contributes to antiglioma immunity by triggering type I IFN induction in glioma microenvironment. Moreover, intratumoral administration of STING agonist improved the efficacy of peptide vaccination in a mouse glioma model, suggesting the rational use of STING agonists in the immunotherapy of brain tumor.

Entities: Disease Gene Species

Keywords: Immunotherapy; STING; glioma; type I IFNs

Year: 2015 PMID： 26137417 PMCID： PMC4485761 DOI： 10.1080/2162402X.2014.999523

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

7 in total

1. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.

Authors: Mitsugu Fujita; Michael E Scheurer; Stacy A Decker; Heather A McDonald; Gary Kohanbash; Edward R Kastenhuber; Hisashi Kato; Melissa L Bondy; John R Ohlfest; Hideho Okada
Journal: Clin Cancer Res Date: 2010-05-14 Impact factor: 12.531

2. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway.

Authors: Lijun Sun; Jiaxi Wu; Fenghe Du; Xiang Chen; Zhijian J Chen
Journal: Science Date: 2012-12-20 Impact factor: 47.728

3. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity.

Authors: Hiroki Ishikawa; Zhe Ma; Glen N Barber
Journal: Nature Date: 2009-09-23 Impact factor: 49.962

4. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer.

Authors: Dinesh Chandra; Wilber Quispe-Tintaya; Arthee Jahangir; Denise Asafu-Adjei; Ilyssa Ramos; Herman O Sintim; Jie Zhou; Yoshihiro Hayakawa; David K R Karaolis; Claudia Gravekamp
Journal: Cancer Immunol Res Date: 2014-06-09 Impact factor: 11.151

5. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.

Authors: Takayuki Ohkuri; Arundhati Ghosh; Akemi Kosaka; Jianzhong Zhu; Maki Ikeura; Michael David; Simon C Watkins; Saumendra N Sarkar; Hideho Okada
Journal: Cancer Immunol Res Date: 2014-10-09 Impact factor: 11.151

6. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP.

Authors: Andrea Ablasser; Jonathan L Schmid-Burgk; Inga Hemmerling; Gabor L Horvath; Tobias Schmidt; Eicke Latz; Veit Hornung
Journal: Nature Date: 2013-09-29 Impact factor: 49.962

7. Identification and characterization of a loss-of-function human MPYS variant.

Authors: L Jin; L-G Xu; I V Yang; E J Davidson; D A Schwartz; M M Wurfel; J C Cambier
Journal: Genes Immun Date: 2011-01-20 Impact factor: 2.676

7 in total

8 in total

1. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.

Authors: Gilles Berger; Erik H Knelson; Jorge L Jimenez-Macias; Michal O Nowicki; Saemi Han; Eleni Panagioti; Patrick H Lizotte; Kwasi Adu-Berchie; Alexander Stafford; Nikolaos Dimitrakakis; Lanlan Zhou; E Antonio Chiocca; David J Mooney; David A Barbie; Sean E Lawler
Journal: Proc Natl Acad Sci U S A Date: 2022-07-05 Impact factor: 12.779

Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy.

1. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.

2. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway.

3. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity.

4. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer.

5. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.

6. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP.

7. Identification and characterization of a loss-of-function human MPYS variant.

1. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.

Review 2. Single vs. combination immunotherapeutic strategies for glioma.

Review 3. STING, DCs and the link between innate and adaptive tumor immunity.

Review 4. Chromosome instability and aneuploidy as context-dependent activators or inhibitors of antitumor immunity.

5. Clinical significance of STING expression and methylation in lung adenocarcinoma based on bioinformatics analysis.

Review 6. STING: infection, inflammation and cancer.

Review 7. cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response.

8. The landscape of host genetic factors involved in immune response to common viral infections.